Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C

被引:3
|
作者
Staettermayer, Albert Friedrich [1 ]
Rutter, Karoline [1 ]
Beinhardt, Sandra [1 ]
Scherzer, Thomas-Matthias [1 ]
Stadlmayr, Andreas [2 ]
Hofer, Harald [1 ]
Wrba, Fritz [3 ]
Steindl-Munda, Petra [1 ]
Krebs, Michael [4 ]
Datz, Christian [2 ]
Trauner, Michael [1 ]
Ferenci, Peter [1 ]
机构
[1] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, A-1090 Vienna, Austria
[2] KH Oberndorf, Dept Internal Med, Oberndorf, Austria
[3] Med Univ Vienna, Dept Clin Pathol, A-1090 Vienna, Austria
[4] Med Univ Vienna, Div Endocrinol, Dept Internal Med 3, A-1090 Vienna, Austria
关键词
Chronic hepatitis C; IL28B; Insulin resistance; PNPLA3; FATTY LIVER-DISEASE; SUSTAINED VIROLOGICAL RESPONSE; PEGINTERFERON PLUS RIBAVIRIN; TREATMENT-NAIVE PATIENTS; GENETIC-VARIATION; RECEPTOR SUBSTRATE-1; STEATOSIS; FIBROSIS; MECHANISMS; PNPLA3;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Insulin resistance, fibrosis and steatosis are established predictors of response to peg-interferon/ribavirin therapy in chronic hepatitis C (CHC). Several host genetic polymorphisms (IL28B, PNPLA3) modify treatment-outcome, the degree of steatosis or fibrosis. The aim of our study was to evaluate the role of these polymorphisms on insulin resistance (IR) in treatment-naive patients with chronic hepatitis C. Methods: Two hundred and two non-diabetic CHC patients (GT1: 181, GT4: 21; m = 126, f = 76) undergoing liver biopsy in two tertiary academic centers were studied. The SNPs rs12979860 (IL28B) and rs738409 (PNPLA3) were investigated by RT-PCR. HOMA-IR, BMI, stage of fibrosis, extent of steatosis, and genetic data were analyzed. Results: Insulin resistance (HOMA-IR >= 3.0) was associated with rs12979860 genotype, presence of advanced fibrosis, and higher BMI. HOMA-IR in CC and in TC/TT was 2.08 +/- 1.61 (mean +/- SD) and 2.94 +/- 2.89 (p = 0.041), respectively. HOMA-IR was higher in advanced than in mild fibrosis (F3-4: 3.92 +/- 3.15; F0-2: 2.38 +/- 2.38; p = 0.004). The percentage of steatotic hepatocytes was higher in patients with advanced fibrosis (21.3 +/- 21.5 vs. 9.1 +/- 14.2; p <0.001), HOMA-IR >= 3.0 (17.7 +/- 17.8 vs. 8.8 +/- 15.4%; p <0.001), and BMI >25.0 kg/m(2) (14.7 +/- 17.0 vs. 9.1 +/- 16.1; p < 0.001). The rs738409 GG genotype was associated with advanced fibrosis and steatosis, but not with HOMA-IR. Multivariable logistic regression identified advanced fibrosis (OR: 2.820, 95% CI: 1.344-5.917; p = 0.006) and the IL28B genotype non-CC (OR: 3.000, 1.348-6.676; p = 0.007) as independent risk factors for insulin resistance. Conclusions: Insulin resistance is more common in carriers of the T allele of SNP rs12979860 than in CC homozygotes and may partly explain the poor outcome of peginterferon/ribavirin therapy in these patients. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:492 / 498
页数:7
相关论文
共 50 条
  • [31] IL28B single nucleotide polymorphisms in the treatment of hepatitis C
    Lange, Christian M.
    Zeuzem, Stefan
    JOURNAL OF HEPATOLOGY, 2011, 55 (03) : 692 - 701
  • [32] IL28B rs12980275 Polymorphism Shows Association With Response to Treatment in Pakistani Patients With Chronic Hepatitis C
    Shaikh, Naila
    Waryah, Ali Muhammad
    Devrajani, Bikha Ram
    Rajput, Muhammad Irfan
    Hayat, Atif Sitwat
    Shaikh, Samiullah
    JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (05) : 814 - 820
  • [33] Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
    Jeong, Seok Hoo
    Jung, Young Kul
    Yang, Jae Won
    Park, Sang Jin
    Kim, Jong Woo
    Kwon, Oh Sang
    Kim, Yun Soo
    Choi, Duck Joo
    Kim, Ju Hyun
    CLINICAL AND MOLECULAR HEPATOLOGY, 2012, 18 (04) : 360 - 367
  • [34] Insulin resistance and chronic hepatitis C
    Tkachenko, L. I.
    Maleev, V. V.
    TERAPEVTICHESKII ARKHIV, 2016, 88 (11) : 29 - 36
  • [35] Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism
    del Campo, J. A.
    Ampuero, J.
    Rojas, L.
    Conde, M.
    Rojas, A.
    Maraver, M.
    Millan, R.
    Garcia-Valdecasas, M.
    Garcia-Lozano, J. R.
    Gonzalez-Escribano, M. F.
    Romero-Gomez, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (01) : 74 - 80
  • [36] Role of IL28B for chronic hepatitis C treatment toward personalized medicine
    Matsuura, Kentaro
    Watanabe, Tsunamasa
    Tanaka, Yasuhito
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (02) : 241 - 249
  • [37] IL28B and the Control of Hepatitis C Virus Infection
    Balagopal, Ashwin
    Thomas, David L.
    Thio, Chloe L.
    GASTROENTEROLOGY, 2010, 139 (06) : 1865 - 1876
  • [38] Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naive Patients With Chronic Hepatitis C
    Staettermayer, Albert Friedrich
    Stauber, Rudolf
    Hofer, Harald
    Rutter, Karoline
    Beinhardt, Sandra
    Scherzer, Thomas Matthias
    Zinober, Kerstin
    Datz, Christian
    Maieron, Andreas
    Dulic-Lakovic, Emina
    Kessler, Harald H.
    Steindl-Munda, Petra
    Strasser, Michael
    Krall, Christoph
    Ferenci, Peter
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (04) : 344 - U94
  • [39] METABOLIC SYNDROME AND INSULIN RESISTANCE IN PATIENTS WITH CHRONIC HEPATITIS C
    Baizhanova, Zh Zh
    Ignatova, T. M.
    Nekrasova, T. P.
    TERAPEVTICHESKII ARKHIV, 2010, 82 (10) : 51 - 56
  • [40] Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C
    Petta, Salvatore
    Ferraro, Donatella
    Camma, Calogero
    Cabibi, Daniela
    Di Cristina, Antonietta
    Di Marco, Vito
    Di Stefano, Rosa
    Grimaudo, Stefania
    Mazzola, Alessandra
    Levrero, Massimo
    Scazzone, Concetta
    Craxi, Antonio
    ANTIVIRAL THERAPY, 2012, 17 (05) : 823 - 831